Incyte (NASDAQ:INCY – Get Free Report) had its price target upped by stock analysts at BMO Capital Markets from $112.00 to $130.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. BMO Capital Markets’ price target would suggest a potential upside of 1.24% from the stock’s previous close. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $116.50. HC Wainwright raised its Buy price target from $140 to $150, while UBS reiterated Hold with a $113 target, suggesting the recent rally may have limited near-term upside according to UBS. Incyte Company Profile(Get Free Report)Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation.